Immunogene therapy with interleukin-2-secreting fibroblasts for intracerebrally metastasizing breast cancer in mice

被引:21
作者
Deshmukh, P
Glick, RP
Lichtor, T
Moser, R
Cohen, EP
机构
[1] Cook Cty Hosp, Dept Neurol Surg, Chicago, IL 60612 USA
[2] Univ Illinois, Dept Neurosurg, Peoria, IL USA
[3] Rush Med Coll, Chicago, IL 60612 USA
[4] Loyola Univ, Dept Neurol Surg, Chicago, IL 60611 USA
[5] Univ Illinois, Dept Anat & Cell Biol, Chicago, IL USA
[6] Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60680 USA
关键词
gene therapy; breast cancer; brain neoplasm; interleukin-2; tumor vaccine; mouse;
D O I
10.3171/jns.2001.94.2.0287
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Object. Breast cancer is the second leading cause of cancer-related death in American women. Brain metastases occur in 15 to 30% of patients with breast cancer, and this usually results in death. Despite the availability of surgery, radiotherapy, and chemotherapy, the prognosis for patients with breast cancer that has metastasized to the intracerebral region remains poor. This study was designed to determine if an intracerebrally metastasizing breast tumor could be treated successfully with a cellular vaccine consisting of allogeneic fibroblasts (H-2(K)) modified to secrete interleukin (IL)-2. Methods. The authors used EO771 breast cancer cells, derived from a spontaneously arising breast-cancer tumor in C57BL/6 mice. The authors first determined the length of survival of C57BL/6 mice that had been injected with varying numbers of EO771 cells into the right frontal lobes and found that 100% of those animals that received a dose of 10(4) cells died within 41 days, whereas 100% of the group that received 10(3) cells died within 23 days. Based on these results, 5 x 10(4) EO771 cells were injected into the right frontal lobe of C57BL/6 mice and the animals were treated intracerebrally with a single intratumoral injection of 10(6) allogeneic fibroblasts genetically engineered to secrete IL-2. The allogeneic fibroblasts transfected with the IL-2 gene formed large quantities of IL-2 as measured by an enzyme-linked immunosorbent assay. Control groups of animals were treated with either allogeneic fibroblasts transfected with the retroviral vector, but not the IL-2 gene, or with media. The effects of this treatment on the animal's survival and the tumor's histopathological characteristics were investigated. The results indicate a significant prolongation (p < 0.005) of survival in animals with intracerebrally metastasizing breast cancer treated only with IL-2-secreting allogeneic fibroblasts. Tumor did not develop in four of 10 animals in the IL-2-treated group, and these animals were rechallenged at 90 days by intracerebral injection of tumor, but no treatment cells, and compared with four naive animals receiving intracerebral tumor. Again, animals that previously had been treated with IL-2-secreting fibroblasts had a markedly prolonged survival (p < 0.05) compared with control animals following a second challenge with tumor cells. Histopathological examination revealed smaller tumors associated with lymphocytic infiltrations in the treated animals. Conclusions. This work represents a new treatment for breast cancer that has metastasized to the brain in which a cellular vaccine consisting of allogeneic fibroblasts genetically engineered to secrete cytokines is used as a novel means for delivery of immunogene therapy and demonstrates the induction of long-term immunity against tumor.
引用
收藏
页码:287 / 292
页数:6
相关论文
共 34 条
[1]   INTRATUMORAL LAK CELL AND INTERLEUKIN-2 THERAPY OF HUMAN GLIOMAS [J].
BARBA, D ;
SARIS, SC ;
HOLDER, C ;
ROSENBERG, SA ;
OLDFIELD, EH .
JOURNAL OF NEUROSURGERY, 1989, 70 (02) :175-182
[2]   HYPOPROTHROMBINEMIA ASSOCIATED WITH INTERLEUKIN-2 THERAPY - CORRECTION WITH VITAMIN-K [J].
BIRCHFIELD, GR ;
RODGERS, GM ;
GIRODIAS, KW ;
WARD, JH ;
SAMLOWSKI, WE .
JOURNAL OF IMMUNOTHERAPY, 1992, 11 (01) :71-75
[3]   HUMAN GENE MAGE-1, WHICH CODES FOR A TUMOR-REJECTION ANTIGEN, IS EXPRESSED BY SOME BREAST-TUMORS [J].
BRASSEUR, F ;
MARCHAND, M ;
VANWIJCK, R ;
HERIN, M ;
LETHE, B ;
CHOMEZ, P ;
BOON, T .
INTERNATIONAL JOURNAL OF CANCER, 1992, 52 (05) :839-841
[4]   A NEW DOMINANT HYBRID SELECTIVE MARKER FOR HIGHER EUKARYOTIC CELLS [J].
COLBEREGARAPIN, F ;
HORODNICEANU, F ;
KOURILSKY, P ;
GARAPIN, AC .
JOURNAL OF MOLECULAR BIOLOGY, 1981, 150 (01) :1-14
[5]   HUMAN-BRAIN TUMOR-DERIVED CELL-LINES - GROWTH-RATE REDUCED BY HUMAN FIBROBLAST INTERFERON [J].
COOK, AW ;
CARTER, WA ;
NIDZGORSKI, F ;
AKHTAR, L .
SCIENCE, 1983, 219 (4586) :881-883
[6]  
de Zoeten E, 1999, J IMMUNOL, V162, P6934
[7]  
FEARON ER, 1988, CANCER RES, V48, P2975
[8]   Expression of MAGE and BAGE genes in Japanese breast cancers [J].
Fujie, T ;
Mori, M ;
Ueo, H ;
Sugimachi, K ;
Akiyoshi, T .
ANNALS OF ONCOLOGY, 1997, 8 (04) :369-372
[9]   PARTIAL SUPPRESSION OF ANCHORAGE-INDEPENDENT GROWTH AND TUMORIGENICITY IN IMMUNODEFICIENT MICE BY TRANSFECTION OF THE H-2 CLASS-I GENE H-2LD INTO A HUMAN-COLON CANCER CELL-LINE (HCT) [J].
GATTONICELLI, S ;
WILLETT, CG ;
RHOADS, DB ;
SIMON, B ;
STRAUSS, RM ;
KIRSCH, K ;
ISSELBACHER, KJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (22) :8543-8547
[10]   Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma [J].
Glick, RP ;
Lichtor, T ;
Mogharbel, A ;
Taylor, CA ;
Cohen, EP .
NEUROSURGERY, 1997, 41 (04) :898-906